Companies › CNTA
CENTESSA PHARMACEUTICALS PLC (CNTA)
Institutional ownership, SEC filings and insider activity
Sector: Healthcare & Pharma · SEC CIK 0001847903 · EDGAR filings · Updated 2026-07-08
CENTESSA PHARMACEUTICALS PLC (CNTA) has reported institutional ownership of 96.2%, with 160 institutional managers holding positions valued at $5.90B per the latest 13F reporting period. SEC filings include an active notice of delisting or failure to satisfy a continued listing rule (8-K Item 3.01), triggering event that accelerates or increases a direct financial obligation (8-K Item 2.04).
Latest updates
- 2026-07-08 — SCHEDULE 13G/A filed
- 2026-07-06 — 15-12G filed
- 2026-06-26 — SCHEDULE 13D/A filed
- 2026-06-24 — SCHEDULE 13D filed
- 2026-06-24 — Insider transaction reported (Form 4)
- 2026-06-24 — Insider transaction reported (Form 4)
Institutional ownership overview
According to SEC 13F filings tracked by Sightfile, CENTESSA PHARMACEUTICALS PLC has 160 institutional holders and institutional ownership of 96.2%.
Insider activity
Insiders reported 97 transactions (2 buys, 46 sells) across 10 reporting insiders, with a net reported value of −$18.2M.
Data flags from SEC filings
Related companies
GLAUKOS CORP (GKOS) · ALKERMES PLC (ALKS) · CG ONCOLOGY INC (CGON) · XENON PHARMACEUTICALS INC (XENE) · TELEFLEX INCORPORATED (TFX) · CELCUITY INC (CELC)
See full history, cross-references and alerts on SightfileData sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-07-08.